Obtaining Highly Active Catalytic Antibodies Capable of Enzymatically Cleaving Antigens.

FRET substrate Ni-NTA affinity column PD-1 amyloid-beta catalytic antibody light chain size-exclusion chromatography

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
18 Nov 2022
Historique:
received: 14 10 2022
revised: 15 11 2022
accepted: 16 11 2022
entrez: 26 11 2022
pubmed: 27 11 2022
medline: 30 11 2022
Statut: epublish

Résumé

A catalytic antibody has multiple functions compared with a monoclonal antibody because it possesses unique features to digest antigens enzymatically. Therefore, many catalytic antibodies, including their subunits, have been produced since 1989. The catalytic activities often depend on the preparation methods and conditions. In order to elicit the high catalytic activity of the antibodies, the most preferable methods and conditions, which can be generally applicable, must be explored. Based on this view, systematic experiments using two catalytic antibody light chains, #7TR and H34, were performed by varying the purification methods, pH, and chemical reagents. The experimental results obtained by peptidase activity tests and kinetic analysis, revealed that the light chain's high catalytic activity was observed when it was prepared under a basic condition. These data imply that a small structural modulation of the catalytic antibody occurs during the purification process to increase the catalytic activity while the antigen recognition ability is kept constant. The presence of NaCl enhanced the catalytic activity. When the catalytic light chain was prepared with these preferable conditions, #7TR and H34 hugely enhanced the degradation ability of Amyloid-beta and PD-1 peptide, respectively.

Identifiants

pubmed: 36430828
pii: ijms232214351
doi: 10.3390/ijms232214351
pmc: PMC9697424
pii:
doi:

Substances chimiques

Antibodies, Catalytic 0
Antigens 0
Immunoglobulin Light Chains 0
Antibodies, Monoclonal 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministry of Education, Culture, Sports, Science and Technology of 676 Japan, and JST-CREST Programs (Japan Science and Technology Agency).
ID : KAKENHI Grant Number 20K21255

Références

J Biol Chem. 2008 Jan 11;283(2):899-907
pubmed: 17991752
Science. 1989 Jun 9;244(4909):1158-62
pubmed: 2727702
J Am Chem Soc. 2011 Sep 28;133(38):15015-24
pubmed: 21861493
Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15954-9
pubmed: 21896761
Int J Mol Sci. 2014 Apr 15;15(4):6399-411
pubmed: 24739811
FASEB Bioadv. 2019 Jan 29;1(2):93-104
pubmed: 32123823
FASEB J. 2015 Jun;29(6):2347-58
pubmed: 25713031
Biochem J. 2006 May 1;395(3):473-81
pubmed: 16422668
J Biol Chem. 2015 Apr 17;290(16):10229-41
pubmed: 25724648
Sci Adv. 2020 Mar 25;6(13):eaay6441
pubmed: 32232151
J Biol Chem. 2017 Jan 13;292(2):417-434
pubmed: 27872188
Acta Crystallogr D Biol Crystallogr. 2014 Mar;70(Pt 3):708-19
pubmed: 24598740
Mol Immunol. 2009 Nov;47(1):87-95
pubmed: 19201029
J Biol Chem. 2008 Feb 22;283(8):4714-22
pubmed: 18086674
J Chromatogr B Biomed Sci Appl. 2001 Mar 10;752(2):233-45
pubmed: 11270864
FASEB J. 2017 Apr;31(4):1668-1677
pubmed: 28096233
J Mol Recognit. 2011 Jan-Feb;24(1):45-59
pubmed: 20140974
J Biol Chem. 1991 Aug 25;266(24):15571-4
pubmed: 1908455
Biochem Biophys Res Commun. 1994 Oct 14;204(1):57-62
pubmed: 7945392
J Biol Chem. 2009 Nov 27;284(48):33079-87
pubmed: 19801545
Biochemistry (Mosc). 2011 Sep;76(9):1065-72
pubmed: 22082277
Nat Med. 1999 Sep;5(9):1044-7
pubmed: 10470082
Biochimie. 2010 May;92(5):545-54
pubmed: 20138955
FASEB J. 2016 Feb;30(2):895-908
pubmed: 26527062
Methods Enzymol. 1997;289:44-67
pubmed: 9353717
Mol Biol (Mosk). 2006 Sep-Oct;40(5):857-64
pubmed: 17086987
RSC Chem Biol. 2020 Dec 10;2(1):220-229
pubmed: 34458785
Biotechnol Bioeng. 2004 Apr 20;86(2):217-25
pubmed: 15052642
Biotechnol Bioeng. 2003 Nov 20;84(4):485-93
pubmed: 14574707
FEBS J. 2010 Sep;277(18):3823-32
pubmed: 20718866
J Biol Chem. 2004 Sep 17;279(38):39611-9
pubmed: 15269209
Mol Immunol. 1999 Dec;36(18):1215-22
pubmed: 10684961
J Biol Chem. 2013 Jul 5;288(27):19558-68
pubmed: 23677996
J Biol Chem. 1994 Dec 23;269(51):32389-93
pubmed: 7798238
FASEB J. 2012 Apr;26(4):1607-15
pubmed: 22205784
FEBS J. 2005 Sep;272(17):4497-505
pubmed: 16128818
J Biol Chem. 2012 Mar 23;287(13):9940-9951
pubmed: 22303018
J Immunol Methods. 2002 Nov 1;269(1-2):283-98
pubmed: 12379368
Appl Microbiol Biotechnol. 2007 Dec;77(3):597-603
pubmed: 17899065
J Mol Recognit. 2011 Nov-Dec;24(6):960-74
pubmed: 22038803
J Biol Chem. 2008 Dec 26;283(52):36724-33
pubmed: 18974093
Science. 1992 May 1;256(5057):665-7
pubmed: 1585181

Auteurs

Tamami Nonaka (T)

Institute for Research Management, Oita University, 700 Dannoharu, Oita 870-1192, Japan.

Hiroaki Taguchi (H)

Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, 3500-3 Minamitamagaki-cho, Suzuka 510-0293, Japan.

Taizo Uda (T)

Nanotechnology Laboratory, Institute of Systems, Information Technologies and Nanotechnologies (ISIT), 4-1 Kyudai-shinmachi, Fukuoka 879-5593, Japan.

Emi Hifumi (E)

Institute for Research Management, Oita University, 700 Dannoharu, Oita 870-1192, Japan.
Research Center for GLOBAL/LOCAL Infectious Diseases, Oita University, 700 Dannoharu, Oita 870-1192, Japan.

Articles similaires

Humans Amyotrophic Lateral Sclerosis Male Middle Aged Female
Anthraquinones Kinetics Water Purification Adsorption Thermodynamics
1.00
Humans Pyrophosphatases Protein Conformation Molecular Dynamics Simulation Kinetics
Humans Epitopes Antibodies, Monoclonal Immunoglobulin Fab Fragments Cryoelectron Microscopy

Classifications MeSH